Vrdn.O

Viridian Therapeutics maintains a conservative capital structure with zero debt relative to equity, resulting in a debt-to-equity ratio of 0.0. The company holds total assets of $899.4 million against total liabilities of $177.3 million, leaving total equity at $722.2 million. Despite this strong balance sheet, the firm faces significant liquidity pressure from operations, reporting an operating cash flow of -$276.4 million. Capital expenditures are minimal at $0.5 million, indicating that cash burn is driven primarily by operating expenses rather than asset investment. The current market capitalization stands at $1.93 billion, implying a price-to-book ratio of 2.67.

Profitability metrics reflect the early-stage nature of the business, with a net income of -$342.6 million and an operating income of -$363.4 million. This results in a negative return on equity of -47.44% and a negative return on assets of -38.09%. Without cohort median data for direct comparison, these figures are consistent with pre-commercial biotechnology firms that prioritize research and development over immediate earnings. The company generated $70.8 million in revenue, which is insufficient to cover its substantial operating losses.

Revenue concentration and geographic exposure details are not provided in the available data. The company reports a single revenue figure of $70.8 million, but no segment breakdown or regional distribution is disclosed. Consequently, specific insights into customer concentration or geographic risk cannot be derived from the current financial snapshot.

Growth trajectory analysis is limited by the absence of historical period data. The current revenue of $70.8 million provides a baseline, but without prior annual or quarterly figures, year-over-year growth rates cannot be calculated. The company’s financial profile suggests a focus on clinical development rather than top-line expansion in the current period.

Risk assessment indicates low dilution risk, supported by the fact that basic and diluted shares outstanding are identical at 101.8 million. However, liquidity risk is flagged as unknown due to insufficient balance-sheet inputs for a precise assessment, despite the company holding significant equity. The primary risk remains the ability to sustain operations given the negative operating cash flow, although the debt-free status provides a buffer against immediate solvency concerns.

Recent observations highlight strong analyst sentiment, with a mean recommendation of 1.78 (where 1 is strong buy). The mean price target is $31.69, with a median of $31.00, suggesting significant upside potential from the current market price of $18.92. The high price target of $50.00 and low of $19.00 indicate a wide range of expectations among analysts. Recent system events confirm the company is under active review for analysis coverage.